Although the correlation between TP53 mutations and OS in PAAD patients has been well substantiated (13–15), the effect of TP53 mutation on PAAD-specific TiME has not been thoroughly investigated. The gene discussed is TP53; the disease is pancreatic adenocarcinoma.